Spinal Disorders Market

Market Overview:

The 7 major spinal disorders markets reached a value of US$ 5.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 7.1 Billion by 2034, exhibiting a growth rate (CAGR) of 3.09% during 2024-2034.

The spinal disorders market has been comprehensively analyzed in IMARC's new report titled "Spinal Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Spinal disorders refer to a broad array of conditions that affect the structures and functions of the spine. Some of the common symptoms associated with the ailments include localized or radiating pain, stiffness, reduced range of motion in the affected area of the spine, etc. In addition to this, nerve compression or irritation may cause tingling or weakness in the back, neck, or extremities. Many spinal disorders can also lead to postural abnormalities, such as curvature of the spine or an exaggerated hunchback posture. Depending on the specific condition, additional symptoms may include difficulty walking, muscle spasms, bowel or bladder dysfunction, paralysis, etc. The diagnosis of spinal disorders involves a comprehensive evaluation by healthcare professionals, typically orthopedic specialists, neurologists, or spine specialists. The diagnostic process may consist of a detailed medical history, a physical examination, and several imaging procedures, like X-rays, MRI scans, CT scans, etc., to assess the structure and condition of the spine. Various additional tests, such as electromyography (EMG) and nerve conduction studies, may be conducted to evaluate nerve function. Furthermore, blood tests and numerous other laboratory investigations can help to identify underlying causes or rule out certain conditions.

The increasing incidences of congenital or developmental abnormalities of the spine that can cause spinal instability, deformities, or nerve compression are primarily driving the spinal disorders market. Furthermore, the rising prevalence of several associated risk factors, such as degenerative changes, traumatic events like falls and motor vehicle accidents, prolonged poor posture, improper body mechanics, spinal infections, etc., is creating a positive outlook for the market. Apart from this, the widespread adoption of facet joint injections, nerve blocks, and epidural steroid injections for providing temporary pain relief and reducing inflammation in specific areas of the spine is also bolstering the market growth. Moreover, the emerging popularity of minimally invasive techniques, such as percutaneous discectomy and vertebroplasty/kyphoplasty, since they involve smaller incisions, minimal tissue disruption, and shorter recovery times compared to traditional open surgery, is acting as another significant growth-inducing factor. Additionally, the escalating utilization of novel interventions, including platelet-rich plasma (PRP) injections and stem cell therapy, to promote tissue healing and stimulate tissue regeneration is expected to drive the spinal disorders market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the spinal disorders market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for spinal disorders and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the spinal disorders market in any manner.

Recent Developments:

• In October 2023, Genentech revealed positive findings from the primary analysis of the ongoing RAINBOWFISH trial, which is evaluating the efficacy and safety of Evrysdi (risdiplam) in newborns with pre-symptomatic spinal muscular atrophy (n=26), aged birth to 6 weeks. The RAINBOWFISH research accomplished its primary aim, with 80% of newborns sitting without support for at least 5 seconds following one year of Evrysdi therapy.

Key Highlights:

• The overall prevalence of demonstrated spinal degenerative disease is observed to be 27.3%, which grew with age.
• Spinal cord injury (SCI) affects more than 15 million people worldwide.
• SCI is a significant source of long-term disability, accounting for about 4.5 million years of life living with disability.
• According to research, women have a higher prevalence of spondylosis and low back pain (7.8% and 76.2%) than men (73.9% and 3.3%, respectively).
• Low back pain (LBP) is a prevalent spinal disorder and the most common cause of disability in the population of the United States under the age of 45.
• Every year, 102 million people (1.4%) are diagnosed with spinal stenosis around the world.

Drugs:

Lyrica is a brand-name pharmaceutical drug. It is FDA-approved for usage in adults for a variety of disorders, including diabetic neuropathy pain, shingles, spinal cord injury, fibromyalgia, and partial onset seizures.

SPINRAZA is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide used to treat spinal muscular atrophy (SMA) in both children and adults. SPINRAZA is delivered intrathecally by healthcare practitioners who have performed lumbar punctures before.

Evrysdi is a survival motor neuron 2 (SMN2) splicing modifier intended to treat spinal muscular atrophy caused by chromosome 5q mutations that result in SMN protein shortage. Evrysdi is taken in liquid form at home every day, non-invasively through the mouth or feeding tube.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the spinal disorders market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the spinal disorders market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current spinal disorders marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the spinal disorders market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the spinal disorders market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the spinal disorders market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of spinal disorders across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of spinal disorders by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of spinal disorders by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with spinal disorders across the seven major markets?
• What is the size of the spinal disorders patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of spinal disorders?
• What will be the growth rate of patients across the seven major markets?
   

Spinal Disorders: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for spinal disorders drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the spinal disorders market?
• What are the key regulatory events related to the spinal disorders market?
• What is the structure of clinical trial landscape by status related to the spinal disorders market?
• What is the structure of clinical trial landscape by phase related to the spinal disorders market?
• What is the structure of clinical trial landscape by route of administration related to the spinal disorders market?